J07CA06 - Diphtheria-Haemophilus Influenzae B-Pertussis-Poliomyelitis-Tetanus |
Probably not porphyrinogenic |
PNP |
Rationale
Based on the pharmacokinetics of the diphtheria-hemophilus influenzae B-pertussis-poliomyelitis-tetanus vaccine (DTP-IPV-Hib), there are no conceivable porphyrinogenic effects.
Chemical description
Diphtheria Toxoid, Tetanus Toxoid, Pertussis Toxoid, inactivated poliovirus (type 1,2 and 3) and Haemophilus influenzae Type b Polysaccharide (DTP-IPV-Hib)
Therapeutic characteristics
The DTP-IPV-Hib vaccine is indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type B disease from the age of 2 months. It is administered by intramuscular injections according to a three or four dose schedule.
Metabolism and pharmacokinetics
The DTP-IPV-Hib vaccine is not metabolized by the cytochrome P450 system.
Similar drugs
References
| # | Citation details | PubMed ID |
|---|---|---|
| Government bodies | ||
| 1. | Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015).
|
|
| Summary of Product Characteristics | ||
| 2. | The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). INFANRIX-IPV+Hib. (Last edition: 19.02. 2015).
|
|
Tradenames
Infanrix · Pentavac 
Infanrix · Pentavac 
Infanrix · Pentavac 
Infanrix · Pentaxim 
Infanrix · Pentavac 
Infanrix · Pediacel vaccine 
Infanrix · Pentavac 
Infanrix · Pentavac 
Infanrix 
Infanrix · Pentaxim 
Infanrix · Pediacel · Poliacel 
Infanrix · Pentaxim 
Pentacel 
Infanrix · Pentavac 
Pentavac 
Infanrix · Pentavac 
Pentaxim 
Pentaxim 
Infanrix · Pentaxim 
Infanrix · Pentaxim 
Infanrix · Pentaxim 
Infanrix · Pediacel · Pentaxim 
Vaccines